[
  {
    "ts": "2025-10-31T18:00:00+00:00",
    "headline": "The Craneware Group Hosts 340B Rebate Forum, Confirms No New Vendor Needed for Pilot",
    "summary": "The Craneware Group convened leaders from 25 major U.S. health systems, alongside representatives from Beacon/ESP (Berkeley Research Group) and Apexus, the HRSA 340B Prime Vendor, at its U.S. headquarters this week to align on readiness for the now-approved 340B Rebate Model Pilot Program.",
    "url": "https://finance.yahoo.com/news/craneware-group-hosts-340b-rebate-180000144.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "c6fde06f-d746-35bb-b6b3-01494b0b611b",
      "content": {
        "id": "c6fde06f-d746-35bb-b6b3-01494b0b611b",
        "contentType": "STORY",
        "title": "The Craneware Group Hosts 340B Rebate Forum, Confirms No New Vendor Needed for Pilot",
        "description": "",
        "summary": "The Craneware Group convened leaders from 25 major U.S. health systems, alongside representatives from Beacon/ESP (Berkeley Research Group) and Apexus, the HRSA 340B Prime Vendor, at its U.S. headquarters this week to align on readiness for the now-approved 340B Rebate Model Pilot Program.",
        "pubDate": "2025-10-31T18:00:00Z",
        "displayTime": "2025-10-31T18:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/6e72c71b4f34beb267dc2fdc804ebb1f",
          "originalWidth": 400,
          "originalHeight": 187,
          "caption": "TCG Logo (PRNewsfoto/The Craneware Group)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/84sCBOFrMRcX6FLybSl9WQ--~B/aD0xODc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6e72c71b4f34beb267dc2fdc804ebb1f.cf.webp",
              "width": 400,
              "height": 187,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vL6Y6i5p.8yA86bm2o4kog--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6e72c71b4f34beb267dc2fdc804ebb1f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/craneware-group-hosts-340b-rebate-180000144.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/craneware-group-hosts-340b-rebate-180000144.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRWRF"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-31T14:37:53+00:00",
    "headline": "Bristol-Myers Squibb's Lack of Update on Phase 3 Alzheimer's Trial 'Surprising,' Morgan Stanley Says",
    "summary": "Bristol-Myers Squibb's (BMY) lack of update on its ADEPT-2 phase-3 Alzheimer's psychosis trial or th",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-apos-lack-143753969.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "97dab807-ee97-3761-8484-0c7efcb3a27f",
      "content": {
        "id": "97dab807-ee97-3761-8484-0c7efcb3a27f",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb's Lack of Update on Phase 3 Alzheimer's Trial 'Surprising,' Morgan Stanley Says",
        "description": "",
        "summary": "Bristol-Myers Squibb's (BMY) lack of update on its ADEPT-2 phase-3 Alzheimer's psychosis trial or th",
        "pubDate": "2025-10-31T14:37:53Z",
        "displayTime": "2025-10-31T14:37:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-apos-lack-143753969.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-apos-lack-143753969.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-31T09:42:56+00:00",
    "headline": "Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best NYSE stocks to buy and hold for the next decade. On October 27, Bristol Myers Squibb announced new Week 52 data from its pivotal Phase 3 POETYK PsA-1 trial. These results further confirmed the efficacy and safety of Sotyktu (deucravacitinib) for treating adults with active psoriatic […]",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-confirms-094256387.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "5601bb99-f2c7-360d-b802-330ad4673460",
      "content": {
        "id": "5601bb99-f2c7-360d-b802-330ad4673460",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best NYSE stocks to buy and hold for the next decade. On October 27, Bristol Myers Squibb announced new Week 52 data from its pivotal Phase 3 POETYK PsA-1 trial. These results further confirmed the efficacy and safety of Sotyktu (deucravacitinib) for treating adults with active psoriatic […]",
        "pubDate": "2025-10-31T09:42:56Z",
        "displayTime": "2025-10-31T09:42:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w_.mq2hxLlg_y2nUTx72ng--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6o8Kx8kFVS_oEolQVNGNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-confirms-094256387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-confirms-094256387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-31T09:26:00+00:00",
    "headline": "Atrial Fibrillation Eight-Market Drug Forecast and Market Analysis 2022-2024 & 2025-2032: Market to Remain Dominated by Bayer and Bristol Myers Squibb; Growth Driven by Milvexian Launch",
    "summary": "The AF market offers opportunities driven by new pipeline drugs such as FXI/FXIa inhibitors addressing bleeding concerns and growing prevalence of treated AF cases. However, growth is challenged by generic erosion of NOACs and competition from cost-effective generics, hindering new entry uptake.Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The \"Atrial Fibrillation: Eight-Market Drug Forecast and Market Analysis - Update\" report has been added to ResearchAndMarkets.com's offering.The table below pres",
    "url": "https://finance.yahoo.com/news/atrial-fibrillation-eight-market-drug-092600085.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "6c70e358-5210-32a5-89fb-20e68e1a1e6c",
      "content": {
        "id": "6c70e358-5210-32a5-89fb-20e68e1a1e6c",
        "contentType": "STORY",
        "title": "Atrial Fibrillation Eight-Market Drug Forecast and Market Analysis 2022-2024 & 2025-2032: Market to Remain Dominated by Bayer and Bristol Myers Squibb; Growth Driven by Milvexian Launch",
        "description": "",
        "summary": "The AF market offers opportunities driven by new pipeline drugs such as FXI/FXIa inhibitors addressing bleeding concerns and growing prevalence of treated AF cases. However, growth is challenged by generic erosion of NOACs and competition from cost-effective generics, hindering new entry uptake.Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The \"Atrial Fibrillation: Eight-Market Drug Forecast and Market Analysis - Update\" report has been added to ResearchAndMarkets.com's offering.The table below pres",
        "pubDate": "2025-10-31T09:26:00Z",
        "displayTime": "2025-10-31T09:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/atrial-fibrillation-eight-market-drug-092600085.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/atrial-fibrillation-eight-market-drug-092600085.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "BAYN.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-31T03:22:16+00:00",
    "headline": "Strong Trial Results in Autoimmune Diseases Might Change the Case for Investing in Bristol-Myers Squibb (BMY)",
    "summary": "In October 2025, Bristol-Myers Squibb reported positive Phase 3 and Phase 2 trial results for Sotyktu in psoriatic arthritis and systemic lupus erythematosus, and early promising data on its next-generation CD19-targeted CAR T cell therapy across multiple autoimmune diseases at prominent medical conferences. These clinical trial updates highlight Bristol-Myers Squibb's progress in expanding its immunology portfolio, strengthening its pipeline for potential future regulatory approvals and...",
    "url": "https://finance.yahoo.com/news/strong-trial-results-autoimmune-diseases-032216309.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ebc76e41-60cb-3f60-aaf8-147097b11c39",
      "content": {
        "id": "ebc76e41-60cb-3f60-aaf8-147097b11c39",
        "contentType": "STORY",
        "title": "Strong Trial Results in Autoimmune Diseases Might Change the Case for Investing in Bristol-Myers Squibb (BMY)",
        "description": "",
        "summary": "In October 2025, Bristol-Myers Squibb reported positive Phase 3 and Phase 2 trial results for Sotyktu in psoriatic arthritis and systemic lupus erythematosus, and early promising data on its next-generation CD19-targeted CAR T cell therapy across multiple autoimmune diseases at prominent medical conferences. These clinical trial updates highlight Bristol-Myers Squibb's progress in expanding its immunology portfolio, strengthening its pipeline for potential future regulatory approvals and...",
        "pubDate": "2025-10-31T03:22:16Z",
        "displayTime": "2025-10-31T03:22:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/strong-trial-results-autoimmune-diseases-032216309.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/strong-trial-results-autoimmune-diseases-032216309.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]